MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Начало・Списък с акции・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Затворен

СекторЗдравеопазване

0.27 3.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.27

Максимум

0.28

Ключови измерители
By Trading Economics
Приходи	-2.5M -37M
Продажби	14M 14M
EPS	-0.111
Марж на печалбата	-262.996
Служители	142
EBITDA	10M -23M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+2042.86% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-18M 106M
Предишно отваряне	-3.58
Предишно затваряне	0.27

Настроения в новините

By Acuity

31%

69%

91 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.5207 / 0.7223 Подкрепа & съпротива

Sangamo Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.04.2026 г., 23:26 ч. UTC

Горещи акции

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16.04.2026 г., 20:41 ч. UTC

Значими двигатели на пазара

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16.04.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

16.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16.04.2026 г., 22:51 ч. UTC

Пазарно говорене

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16.04.2026 г., 22:08 ч. UTC

Печалби

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Health Care Roundup: Market Talk

16.04.2026 г., 20:49 ч. UTC

Печалби

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16.04.2026 г., 20:43 ч. UTC

Печалби

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16.04.2026 г., 20:40 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

16.04.2026 г., 20:40 ч. UTC

Пазарно говорене

Печалби

Netflix Says Engagement Quality Hits New High -- Market Talk

16.04.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16.04.2026 г., 20:25 ч. UTC

Печалби

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16.04.2026 г., 20:23 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16.04.2026 г., 20:19 ч. UTC

Печалби

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16.04.2026 г., 20:17 ч. UTC

Печалби

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16.04.2026 г., 20:17 ч. UTC

Печалби

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Сравнение с други в отрасъла

Ценова промяна

Sangamo Therapeutics Inc Прогноза

Ценова цел

By TipRanks

2042.86% нагоре

12-месечна прогноза

Среден 6 USD 2042.86%

Висок 10 USD

Нисък 2 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Sangamo Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Sangamo Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.5207 / 0.7223Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Настроение

By Acuity

91 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.